Clinical research progress on radiopharmaceuticals imaging targeting epidermal growth factor receptor
10.3760/cma.j.cn321828-20201207-00436
- VernacularTitle:靶向表皮生长因子受体核素显像的临床研究进展
- Author:
Xiangming SONG
1
;
Xiaoli LAN
Author Information
1. 华中科技大学同济医学院附属协和医院核医学科、分子影像湖北省重点实验室，武汉 430022
- Keywords:
Receptor, epidermal growth factor;
Isotope labeling;
Antibodies, monoclonal;
Protein-tyrosine kinases;
Trends
- From:
Chinese Journal of Nuclear Medicine and Molecular Imaging
2022;42(7):428-432
- CountryChina
- Language:Chinese
-
Abstract:
Epidermal growth factor receptor (EGFR) plays an important role in the development and occurrence of a variety of malignant tumors. Molecular targeted therapy for EGFR is in the ascendant. Molecular imaging can reveal the expression of EGFR and its mutations in vivo. The molecular probes labeled with 89Zr, 11C and 18F are used for imaging and the main research is about tyrosine kinase inhibitors labeled with 11C. PET is used to visualize EGFR expression and mutations in vivo, which can noninvasively screen patients suitable for targeting treatment and evaluate efficacy. This paper reviews the clinical researches and trials of these probes, and summarizes the clinical value of imaging methods, hoping to provide the evidence for clinical translation and application in the future.
